Monte Rosa Therapeutics, Inc. GLUE Total debt
Total debt at other companies
Other financials
Where this comes from
Calculated from Monte Rosa Therapeutics, Inc.’s reported figures.
Plus components not separately reported this period.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s total debt?
- Monte Rosa Therapeutics, Inc. (GLUE) reported total debt of $39.06M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s total debt changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s total debt decreased by 6.7% year-over-year, from $41.86M to $39.06M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s total debt?
- Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s total debt has grown at a 51.7% compound annual growth rate (CAGR), from $7.4M to $39.19M.
- What does total debt mean?
- Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.